Verrica Pharmaceuticals Inc (VRCA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) has a cash flow conversion efficiency ratio of -0.571x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.16 Million) by net assets ($16.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Verrica Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Verrica Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Verrica Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Verrica Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verrica Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ctek AB
ST:CTEK
|
0.182x |
|
Darwin AG
XETRA:7V0
|
N/A |
|
Multicampus Corporation
KQ:067280
|
0.038x |
|
Balyo SA
PA:BALYO
|
-1.908x |
|
WMG Holdings Bhd
KLSE:6378
|
0.065x |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
0.002x |
|
Kingwaytek Technology Co Ltd
TWO:6516
|
-0.016x |
|
Patria Bank SA
RO:PBK
|
0.240x |
Annual Cash Flow Conversion Efficiency for Verrica Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Verrica Pharmaceuticals Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Verrica Pharmaceuticals Inc (VRCA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.74 Million | $-17.63 Million | -0.712x | -111.53% |
| 2024-12-31 | $-9.86 Million | $-60.93 Million | 6.179x | +416.56% |
| 2023-12-31 | $19.76 Million | $-38.58 Million | -1.952x | -319.00% |
| 2022-12-31 | $40.03 Million | $-18.65 Million | -0.466x | +44.93% |
| 2021-12-31 | $32.60 Million | $-27.58 Million | -0.846x | +7.62% |
| 2020-12-31 | $32.99 Million | $-30.21 Million | -0.916x | -117.23% |
| 2019-12-31 | $65.02 Million | $-27.41 Million | -0.422x | -110.92% |
| 2018-12-31 | $89.43 Million | $-17.87 Million | -0.200x | -130.71% |
| 2017-12-31 | $-7.04 Million | $-4.58 Million | 0.651x | +7.64% |
| 2016-12-31 | $-2.66 Million | $-1.61 Million | 0.605x | -- |
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the tr… Read more